据英国生物技术流报告,其SIRT6基因疗法在老年狗体内安全第二次施用,其结果支持其扩大健康范围的潜力。 UK biotech Genflow reports safe second dosing of its SIRT6 gene therapy in elderly dogs, with results supporting its potential to extend healthspan.

以英国为基地的一家生物技术公司,Gentral Biosciences报告说,在一次概念验证试验中,它第二次使用SIRT6百分百基因疗法后,对老年狗没有产生不良影响。 Genflow Biosciences, a UK-based biotech firm, reported no adverse effects in elderly dogs after a second dose of its SIRT6-centenarian gene therapy in a proof-of-concept trial. 这种疗法来自于人类百岁老人发现的基因变异,安全地给了28只10岁及以上的小狗,预计在2026年1月结束后续研究. The therapy, derived from a gene variant found in human centenarians, was safely administered to 28 beagles aged 10 and older, with follow-up expected to conclude in January 2026. 这些结果支持了治疗的安全性以及扩大动物健康范围的潜力,将动物健康定位为近期商业机会。 The results support the treatment’s safety and potential for extending healthspan in animals, positioning animal health as a near-term commercial opportunity. 该公司还计划推进人类代谢性肝病相关治疗。 The company also plans to advance a related therapy for human metabolic liver disease.